2025
Identifying Daytime Hypercapnia Using Transcutaneous Carbon Dioxide Monitoring in Patients With Amyotrophic Lateral Sclerosis
Morrison A, Jimenez J, Hsu J, Elman L, Choi P, Ackrivo J. Identifying Daytime Hypercapnia Using Transcutaneous Carbon Dioxide Monitoring in Patients With Amyotrophic Lateral Sclerosis. Muscle & Nerve 2025, 71: 611-619. PMID: 39936179, PMCID: PMC11887530, DOI: 10.1002/mus.28366.Peer-Reviewed Original ResearchConceptsPulmonary function testsMaximum inspiratory pressureForced Vital CapacityDaytime hypercapniaAmyotrophic lateral sclerosisClinical significanceValues of maximum inspiratory pressurePrevalence of hypercapniaTranscutaneous carbon dioxide monitoringTranscutaneous carbon dioxideRate of deathRespiratory failureCause of deathLateral sclerosisRetrospective studyProspective studyAmyotrophic lateral sclerosis clinicInspiratory pressurePatient's symptomsFunction testsClinical rolePatientsVital capacityHypercapniaCarbon dioxide monitoringContinued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Song J, Miede C, Dumistracel M, Coeck C, Cottin V. Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON. Lung 2025, 203: 25. PMID: 39789408, PMCID: PMC11717875, DOI: 10.1007/s00408-024-00778-z.Peer-Reviewed Original ResearchConceptsProgressive pulmonary fibrosisForced Vital CapacityAdverse eventsSafety profilePulmonary fibrosisConclusionThe safety profileDiscontinuation of nintedanibExposure to nintedanibSafety of nintedanibOpen-label extensionBaseline to weekFrequent adverse eventsFatal adverse eventsLong-term treatmentLonger-term treatmentNintedanib groupGastrointestinal eventsINBUILD trialNintedanibMethodsAdverse eventsModerate severityPatientsContinuous treatmentVital capacityINBUILD
2024
Initiation of noninvasive ventilation in patients with amyotrophic lateral sclerosis
Jimenez J, Tang M, Wilson M, Morrison A, Ackrivo J, Choi P. Initiation of noninvasive ventilation in patients with amyotrophic lateral sclerosis. Muscle & Nerve 2024, 70: 1099-1103. PMID: 39243146, DOI: 10.1002/mus.28250.Peer-Reviewed Original ResearchConceptsNoninvasive ventilation initiationMaximal inspiratory pressureChronic respiratory failureNoninvasive ventilationNIV initiationAmyotrophic lateral sclerosisRespiratory failureMm HgSingle-center retrospective cohort studyInitiation of noninvasive ventilationTranscutaneous CO<sub>2</sub> (TRetrospective cohort studyCohort of ALS patientsBulbar onset amyotrophic lateral sclerosisDaytime hypercapniaInspiratory forceImproved survivalLateral sclerosisClinical characteristicsInspiratory pressureConcomitant indicationCohort studyPatientsALS patientsEligibility criteriaCross-shift changes in pulmonary function and occupational exposure to particulate matter among e-waste workers in Ghana
Laskaris Z, O'Neill M, Batterman S, Mukherjee B, Fobil J, Robins T. Cross-shift changes in pulmonary function and occupational exposure to particulate matter among e-waste workers in Ghana. Frontiers In Public Health 2024, 12: 1368112. PMID: 38784567, PMCID: PMC11111984, DOI: 10.3389/fpubh.2024.1368112.Peer-Reviewed Original ResearchConceptsE-waste workersExposure to particulate matterE-wasteParticulate matterAgbogbloshie e-waste siteInhalation exposure to particulate matterE-waste sitesBurning e-wasteConcentrations of PMHealth-based guidelinesExposure to airborne pollutantsExposure to PMOccupational exposure to particulate matterCross-shift changesElectronic-wasteForced Vital CapacityPersonal PMPM exposureAirborne pollutantsLinear mixed modelsBreathing zone concentrationsPulmonary functionComparison populationRecovery workersMixed modelsExploiting meta-analysis of genome-wide interaction with serum 25-hydroxyvitamin D to identify novel genetic loci associated with pulmonary function
Seo J, Gaddis N, Patchen B, Xu J, Barr R, O’Connor G, Manichaikul A, Gharib S, Dupuis J, North K, Cassano P, Hancock D. Exploiting meta-analysis of genome-wide interaction with serum 25-hydroxyvitamin D to identify novel genetic loci associated with pulmonary function. American Journal Of Clinical Nutrition 2024, 119: 1227-1237. PMID: 38484975, PMCID: PMC11130669, DOI: 10.1016/j.ajcnut.2024.03.007.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesGenome-wide interactionsGWAS meta-analysesGenome-wide genotypingGenetic variant associationsPathway enrichment analysisGenetic architectureVariant associationsP38 MAPK pathwayAssociation studiesGene-environment interactionsBiological insightsGenetic variantsEnrichment analysisVariant signalsMeta-analyzed resultsMAPK pathwayBiological relevancePathwayForced Vital CapacityEvaluate interactive effectsMeta-analysesVariantsSmoking historyAssociated with FEV<sub>1</sub> an
2023
Sex modifies the risk of HIV-associated obstructive lung disease in Ugandans postpneumonia
Abelman R, Fitzpatrick J, Zawedde J, Sanyu I, Byanyima P, Kaswabuli S, Musisi E, Hsieh J, Gardner K, Zhang M, Byanova K, Sessolo A, Hunt P, Lalitha R, Davis J, Crothers K, Worodria W, Huang L. Sex modifies the risk of HIV-associated obstructive lung disease in Ugandans postpneumonia. AIDS 2023, 37: 1683-1692. PMID: 37352494, PMCID: PMC10527596, DOI: 10.1097/qad.0000000000003626.Peer-Reviewed Original ResearchConceptsObstructive lung diseaseLung diseaseLung functionAbnormal lung functionMultivariable regression modelsWarrants further studyCommon comorbiditiesExpiratory volumeSpirometric abnormalitiesSmoking statusSpirometric testingTB statusVital capacitySex modifiesStratified analysisHIVWomenDiseaseComorbiditiesMenSexFurther studiesGreater degreeRiskTuberculosis
2022
Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung Disease
Yang MM, Balmert LC, Marangoni RG, Carns M, Hinchcliff M, Korman BD, Varga J. Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care & Research 2022, 75: 152-157. PMID: 34251759, PMCID: PMC9233895, DOI: 10.1002/acr.24749.Peer-Reviewed Original ResearchConceptsC1q/tumor necrosis factor-related protein 9Interstitial lung diseaseSystemic sclerosisLung diseaseLung functionSystemic sclerosis-associated interstitial lung diseaseSSc-associated interstitial lung diseasePulmonary function test dataLatent trajectory analysisVital capacity percentWorse lung functionPrimary outcome measureWorse pulmonary functionCause of morbidityRetrospective longitudinal studyAdipose tissue metabolismCross-sectional analysisAdipokine homeostasisDisease stabilityPulmonary functionSSc patientsSerum levelsPatient RegistryPredictive markerCapacity percentLongitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study
Allen RJ, Oldham JM, Jenkins DA, Leavy OC, Guillen-Guio B, Melbourne CA, Ma SF, Jou J, Kim JS, Cooperative C, Fahy WA, Oballa E, Hubbard RB, Navaratnam V, Braybrooke R, Saini G, Roach KM, Tobin MD, Hirani N, Whyte MKB, Kaminski N, Zhang Y, Martinez FJ, Linderholm AL, Adegunsoye A, Strek ME, Maher TM, Molyneaux PL, Flores C, Noth I, Jenkins R, Wain LV. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study. The Lancet Respiratory Medicine 2022, 11: 65-73. PMID: 35985358, PMCID: PMC10077113, DOI: 10.1016/s2213-2600(22)00251-x.Peer-Reviewed Original ResearchMeSH KeywordsGenome-Wide Association StudyHumansIdiopathic Pulmonary FibrosisLungLung Volume MeasurementsVital CapacityConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisLung capacityAmerican Thoracic Society/European Respiratory Society guidelinesDiagnosis of IPFEuropean Respiratory Society guidelinesPotential novel therapeutic approachHealth-National HeartLongitudinal lung functionRespiratory Society guidelinesGenetic variantsNovel therapeutic approachesIncurable lung diseaseMedical Research CouncilProgressive scarringFVC declineLung functionVital capacityBlood InstituteSociety guidelinesLung diseaseNational HeartDisease progressionTherapeutic approachesSignificant associationLong-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study
Raghu G, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research 2022, 23: 129. PMID: 35597980, PMCID: PMC9123757, DOI: 10.1186/s12931-022-02047-0.Peer-Reviewed Original ResearchConceptsOpen-label extensionIdiopathic pulmonary fibrosisWeek 128PRM-151Serious TEAEsPulmonary fibrosisPentraxin 2Efficacy dataRandomized periodTreatment-emergent adverse event profilesOpen-label extension studyAcute respiratory failureAdverse event profileNew safety signalsPatient-reported outcomesLimited efficacy dataLong-term safetyEudraCT 2014Lung transplantationRespiratory failureWalk distanceLong-term evaluationEvent profileVital capacityIntravenous infusion
2021
Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis
Showalter K, Hoffmann A, Richardson C, Aaby D, Lee J, Dematte J, Agrawal R, Savas H, Wu X, Chang RW, Hinchcliff M. Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis. The Journal Of Rheumatology 2021, 48: 1830-1838. PMID: 34266985, PMCID: PMC8985598, DOI: 10.3899/jrheum.210533.Peer-Reviewed Original ResearchConceptsRadiographic interstitial lung diseaseInterstitial lung diseasePulmonary function testsSystemic sclerosisEsophageal dilationPulmonary function declineFVC declineClinical factorsEsophageal diameterFunction declineScl-70 positivitySSc-ILD patientsSubanalysis of patientsScl-70Function testsPrognostic implicationsVital capacityLung diseaseStudy criteriaI autoantibodiesRisk factorsPFT declineDiffusion capacityPatientsLinear mixed effects modelsPredictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease
Assassi S, Li N, Volkmann ER, Mayes MD, Rünger D, Ying J, Roth MD, Hinchcliff M, Khanna D, Frech T, Clements PJ, Furst DE, Goldin J, Bernstein EJ, Castelino FV, Domsic RT, Gordon JK, Hant FN, Shah AA, Shanmugam VK, Steen VD, Elashoff RM, Tashkin DP. Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease. Arthritis & Rheumatology 2021, 73: 1005-1013. PMID: 33350170, PMCID: PMC8169525, DOI: 10.1002/art.41627.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedbeta 2-MicroglobulinChemokine CCL19Chemokine CCL8Chemokine CXCL10Chemokine CXCL9CyclophosphamideFemaleHumansImmunosuppressive AgentsLung Diseases, InterstitialMaleMethotrexateMiddle AgedMycophenolic AcidObservational Studies as TopicPrognosisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis Factor, Type IIScleroderma, SystemicVital CapacityConceptsInterstitial lung diseaseMycophenolate mofetilPredictive significanceCYC armILD courseMMF armSSc-ILDSystemic sclerosisLung diseaseHigh baseline C-reactive protein levelsTumor necrosis factor receptor type IIBaseline C-reactive protein levelsScleroderma Lung Study IIC-reactive protein levelsGood responseVital capacity percentChemotactic protein-2Receptor type IIActive immunosuppressionClinical predictorsCRP levelsObservational cohortProtein scoreActive treatmentTreatment armsImpact of unilateral diaphragm elevation on postoperative outcomes in bilateral lung transplantation – a retrospective single‐center study
Draeger H, Salman J, Aburahma K, Becker L, Siemeni T, Boethig D, Sommer W, Avsar M, Bobylev D, Schwerk N, Müller C, Greer M, Gottlieb J, Welte T, Hoeper M, Hinrichs J, Tudorache I, Kühn C, Haverich A, Warnecke G, Ius F. Impact of unilateral diaphragm elevation on postoperative outcomes in bilateral lung transplantation – a retrospective single‐center study. Transplant International 2021, 34: 474-487. PMID: 33393142, DOI: 10.1111/tri.13812.Peer-Reviewed Original ResearchMeSH KeywordsDiaphragmForced Expiratory VolumeHumansLungLung TransplantationRetrospective StudiesVital CapacityConceptsDiaphragm elevationBilateral lung transplantationLung transplant recipientsLung transplantationPostoperative courseTransplant recipientsRadiological evidenceRetrospective single-center studyLeft diaphragm elevationSingle-center studyLung function testsForced expiratory volumeRight diaphragmDiaphragmatic elevationGraft survivalLeft diaphragmPostoperative outcomesDiaphragmatic heightFollow-upFunction testsExpiratory volumePatientsPermanent elevationLungTransplantation
2020
Associations of marijuana with markers of chronic lung disease in people living with HIV
Wenger D, Triplette M, Shahrir S, Akgun K, Wongtrakool C, Brown, Kim J, Hoo G, Rodriguez‐Barradas M, Huang L, Feemster L, Zifodya J, Crothers K. Associations of marijuana with markers of chronic lung disease in people living with HIV. HIV Medicine 2020, 22: 92-101. PMID: 33022830, DOI: 10.1111/hiv.12966.Peer-Reviewed Original ResearchConceptsChronic lung diseaseLung diseaseMarijuana smokingRadiographic emphysemaMarijuana exposureHIV-Associated Lung Emphysema (EXHALE) studyLarger total lung capacityHIV-positive patientsTotal lung capacityHigh lung volumesCross-sectional analysisMarijuana useAssociation of marijuanaExpiratory volumeTobacco smokingVital capacityLung capacityLung healthLung volumeSmokingWeekly marijuana useHIVPLWHLogistic regressionEmphysemaNintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells A, Flaherty K, Brown K, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts W, Stowasser S, Quaresma M, Goeldner R, Schlenker-Herceg R, Kolb M, investigators I, Abe S, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine 2020, 8: 453-460. PMID: 32145830, DOI: 10.1016/s2213-2600(20)30036-9.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseIdiopathic pulmonary fibrosisIdiopathic non-specific interstitial pneumoniaAutoimmune interstitial lung diseaseUnclassifiable idiopathic interstitial pneumoniaNon-specific interstitial pneumoniaDose of nintedanibParallel-group trialIdiopathic interstitial pneumoniaEffect of nintedanibINBUILD trialInterstitial pneumoniaILD diagnosisHigh-resolution CTILD progressionFVC declineHypersensitivity pneumonitisProgressive fibrosing interstitial lung diseasesOverall populationInterstitial lung disease diagnosisChest imaging featuresProtocol-defined criteriaSafety of nintedanibChronic hypersensitivity pneumonitisDisease subgroup analysesExtracting lung function measurements to enhance phenotyping of chronic obstructive pulmonary disease (COPD) in an electronic health record using automated tools
Akgün KM, Sigel K, Cheung KH, Kidwai-Khan F, Bryant AK, Brandt C, Justice A, Crothers K. Extracting lung function measurements to enhance phenotyping of chronic obstructive pulmonary disease (COPD) in an electronic health record using automated tools. PLOS ONE 2020, 15: e0227730. PMID: 31945115, PMCID: PMC6964890, DOI: 10.1371/journal.pone.0227730.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesData MiningElectronic Health RecordsForced Expiratory VolumeHealth Information SystemsHospitalizationHumansLungNatural Language ProcessingPulmonary Disease, Chronic ObstructiveSeverity of Illness IndexSoftwareUnited StatesUnited States Department of Veterans AffairsVeteransVital CapacityConceptsChronic obstructive pulmonary diseaseVeterans Aging Cohort StudyObstructive pulmonary diseaseFEV1 valuesPulmonary diseasePhenotyping of patientsPulmonary function testsAging Cohort StudyLung function measurementsElectronic health record dataHealth record dataStructured electronic health record dataPositive predictive valueElectronic health recordsAirflow obstructionChart reviewCohort studyExpiratory volumeCOPD phenotypesFunction testsVital capacityFEV1 measurementsData sourcesPredictive valueClinical notes
2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. The Lancet Respiratory Medicine 2019, 7: 657-664. PMID: 31122893, DOI: 10.1016/s2213-2600(19)30172-9.Peer-Reviewed Original ResearchConceptsOpen-label extension studyIdiopathic pulmonary fibrosisPRM-151Adverse eventsLong-term treatmentWalking distanceExtension studyIPF exacerbationsWeek 52Week 76Pulmonary fibrosisIPF progressionDouble-blind treatment periodLife-threatening adverse eventsDouble-blind periodExploratory efficacy analysesSerious adverse eventsSevere adverse eventsMin intravenous infusionLong-term safetyRandom intercept mixed modelChest painPlacebo groupMore patientsEfficacy analysisOmega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10–Pulmonary Function Association
Xu J, Gaddis N, Bartz T, Hou R, Manichaikul A, Pankratz N, Smith A, Sun F, Terzikhan N, Markunas C, Patchen B, Schu M, Beydoun M, Brusselle G, Eiriksdottir G, Zhou X, Wood A, Graff M, Harris T, Ikram M, Jacobs D, Launer L, Lemaitre R, O’Connor G, Oelsner E, Psaty B, Vasan R, Rohde R, Rich S, Rotter J, Seshadri S, Smith L, Tiemeier H, Tsai M, Uitterlinden A, Voruganti V, Xu H, Zilhão N, Fornage M, Zillikens M, London S, Barr R, Dupuis J, Gharib S, Gudnason V, Lahousse L, North K, Steffen L, Cassano P, Hancock D. Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10–Pulmonary Function Association. American Journal Of Respiratory And Critical Care Medicine 2019, 199: 631-642. PMID: 30199657, PMCID: PMC6396866, DOI: 10.1164/rccm.201802-0304oc.Peer-Reviewed Original ResearchMeSH KeywordsAgedalpha-Linolenic AcidBiomarkersDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3Fatty Acids, UnsaturatedFemaleForced Expiratory VolumeGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideRespiratory Physiological PhenomenaSex FactorsSmokingVital CapacityConceptsSNP associationsGenome-wide interaction analysisHeart and Aging ResearchMeta-analysesCohort-specific resultsAssociated with lower FVCGenome-wide analysisGenomic Epidemiology ConsortiumAssociated with FEV<sub>1</sub> anPulmonary function testsEpidemiology ConsortiumFatty acidsEffect modificationFunctional associationN-3 PUFAPulmonary healthLower FVCGenetic susceptibilitySpirometric measurementsCohortPolyunsaturated fatty acidsAssociationMeasures of pulmonary function testsInteraction analysisFVC
2018
A functional macrophage migration inhibitory factor promoter polymorphism is associated with reduced diffusing capacity
Zhang C, Ramsey C, Berical A, Yu L, Leng L, McGinnis K, Song Y, Michael H, McCormack M, Allore H, Morris A, Crothers K, Bucala R, Lee P, Sauler M. A functional macrophage migration inhibitory factor promoter polymorphism is associated with reduced diffusing capacity. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2018, 316: l400-l405. PMID: 30520689, PMCID: PMC6397351, DOI: 10.1152/ajplung.00439.2018.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorChronic obstructive pulmonary diseaseMIF -794 CATTAbnormal diffusion capacityCigarette smoke exposureSmoke exposureAssociation of MIFDiffusion capacityMacrophage migration inhibitory factor (MIF) promoter polymorphismsPathogenesis of COPDChronic cigarette smoke exposureMultivariable logistic regression modelModifiable risk factorsObstructive pulmonary diseaseMigration inhibitory factorCross-sectional analysisLogistic regression modelsCommon genetic polymorphismsInnate immune genesAirflow obstructionMIF expressionCOPD severityPulmonary diseaseMIF allelesRisk factorsRisk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry
Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. The Journal Of Rheumatology 2018, 46: 176-183. PMID: 30275260, DOI: 10.3899/jrheum.180018.Peer-Reviewed Original ResearchConceptsExercise oxygen desaturationPulmonary hypertensionCardiopulmonary hospitalizationsPericardial effusionSystemic sclerosisOxygen desaturationMale sexRisk factorsSSc-pulmonary arterial hypertensionSystolic pulmonary arterial pressurePredictors of hospitalizationRight heart catheterizationPredictors of mortalityProspective cohort studyPulmonary arterial pressurePulmonary function testingSystemic sclerosis patientsBaseline clinical measuresProportional hazards modelPH patientsArterial hypertensionDyspnea scoreHeart catheterizationCohort studyDisease durationPerformance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis
Showalter K, Hoffmann A, Rouleau G, Aaby D, Lee J, Richardson C, Dematte J, Agrawal R, Chang RW, Hinchcliff M. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. The Journal Of Rheumatology 2018, 45: 1572-1576. PMID: 30275265, PMCID: PMC6214765, DOI: 10.3899/jrheum.171362.Peer-Reviewed Original ResearchConceptsScl-70 autoantibodiesPulmonary function testsNegative predictive valueInterstitial lung diseaseSSc-ILDVital capacityLung diseaseSystemic sclerosis-associated interstitial lung diseaseRadiographic interstitial lung diseaseHigh negative predictive valueReceiver-operating characteristic curveForced Vital CapacityILD evaluationChest HRCTSystemic sclerosisFunction testsTomography scanAmerican CollegeFVCDLCOPatientsAutoantibodiesPredictive valueSSc criteriaThoracic radiologists
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply